PA5-29220

antibody from Invitrogen Antibodies

Targeting: PIK3R1 GRB1, p85, p85-ALPHA

Western blot

Immunoprecipitation

Immunohistochemistry

Antibody data

Submit

Validation data

Product number: PA5-29220 - Provider product page
Provider: Invitrogen Antibodies
Product name: PI3K p85 alpha Polyclonal Antibody
Antibody type: Polyclonal
Antigen: Recombinant protein fragment
Description: Recommended positive controls: 293T, Jurkat, K562, THP-1, Neuro 2A, C8D30, NIH-3T3, Raw264.7, C2C12, PC-12, Rat2. Predicted reactivity: Mouse (89%), Rat (87%), Rhesus Monkey (99%), Bovine (94%). Store product as a concentrated solution. Centrifuge briefly prior to opening the vial.
Reactivity: Human, Mouse, Rat
Host: Rabbit
Isotype: IgG
Vial size: 100 µL
Concentration: 0.58 mg/mL
Storage: Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.

PIK3R1 protein structure - PA5-29220 shown in red.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: PI3K p85 alpha Polyclonal Antibody immunoprecipitates PI3 kinase p85 alpha protein in IP experiments. IP samples: Jurkat whole cell extract. A. Control with 5 µg of preimmune Rabbit IgG. B. Immunoprecipitation of PI3 kinase p85 alpha protein by 5 µg PI3K p85 alpha Polyclonal Antibody (Product # PA5-29220). 10 % SDS-PAGE. The immunoprecipitated PI3 kinase p85 alpha protein was detected by PI3K p85 alpha Polyclonal Antibody (Product # PA5-29220) diluted at 1:500.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 4 KFL triggers the PI3K/Akt pathway in ZEA-induced HepG2 cells. ( A ) Cells were treated with KFL (10, 25 and 50 uM) followed by ZEA (40 uM) for 24 h. After the treatment, whole-cell lysates were exposed to Western blotting with anti-pPI3K and anti-pAkt antibodies. Total PI3K and Akt levels were measured as loading controls. ( B ) Cells were pre-treated with a PI3K/Akt inhibitor (LY294002, 30 muM) for 2 h, followed by KFL (50 muM) and/or ZEA (40 muM) for 24 h. Western blot was performed to detect the pAkt, HO-1 and Nrf2 levels by anti-pAkt, anti-HO-1 and anti-Nrf2 abs. Data are represented as the mean +- SD of triplicate values ( n = 3), and * p < 0.05 represents noteworthy discrepancies compared with the control. # p < 0.05 represents significant variations compared with the ZEA alone and KFL with ZEA treatment groups.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 3 KRL enhances cell survival mechanism. H9c2 cells were cultured in serum-free media for 3 h, followed by treatment with KRL for 2 h before or after DOX treatment, respectively. ( A , B ) KRL activates the IGF1R-mediated survival pathway in H9c2 cells. The expression of p-IGF1R, PI3K, p-PI3K, AKT, and p-AKT was analyzed by Western blotting. beta-actin was used as the internal control. ( C ) Representative Western blots showing the changes in MAPK signaling proteins (pP38 and pJNK) in H9c2 cells. Data are represented as the mean +- SD of triplicate values ( n = 3) and * p < 0.05 represents significant variations compared with the control. # p < 0.05 represents significant variations as compared to DOX alone and KRL with DOX treatment groups.